A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors
Recruiting · Phase 1 · NCT06764771
Conditions: Advanced Malignant Tumors
At a glance
- Research payments reported, 2025
- $9,738
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 437
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986488 (drug), Adagrasib (drug), Cetuximab (drug), Nivolumab (drug)
- Dates
- Started 2025-03-25; completion 2027-10-15
- Results posted
- Not yet
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
From ClinicalTrials.gov, last updated 2026-07-29. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $9,738 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Suresh G. Nair, MD Hematology & Oncology · Allentown, PA
- Hans J. Hammers, M.D., PH.D. Medical Oncology · Dallas, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Lehigh Valley Hospital, PA $6,376
- Ut Southwestern Medical Center $3,362
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.